Loading organizations...
§ Venture Capital
No factual information about this organization is available in the provided research to generate a specific meta description.
Fir Brook Capital is a financial organization and investment firm whose specific operational focus, asset classes, and headquarters location are not currently publicly disclosed. Due to a lack of publicly available regulatory filings or official press releases, specific financial metrics such as total funding raised, assets under management, portfolio valuation, or current employee headcount remain completely unavailable at this time. Furthermore, there are no confirmed recognizable names associated with the firm, precluding the listing of specific lead investors, active portfolio companies, or institutional clients. The firm operates within the broader capital markets, though its exact investment stage, industry specialization, and geographic mandate have not been officially verified through standard financial databases or industry directories. The exact founding year and the identities of the original founders of Fir Brook Capital are not currently known.
Fir Brook Capital has 1 tracked investment across 1 company. The latest tracked deal is $5.1B Series C in Regend Therapeutics in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 11, 2026 | Regend Therapeutics | $5.1B Series C | — | Gongqingcheng Fuhui, Hongtai Fund, Yuze Capital, 合肥产投, 合肥高投, 天士力资本 |